What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
CIK: 0001017645
Total reported value
$2.9B
$2.9B
18 檔
94.5%
At the close of Q3 2024, General Atlantic, L.p. disclosed equity holdings valued at approximately $2.9B, spread across 18 reported holdings.
In Q3 2024, General Atlantic, L.p. adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 1 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including ALHC, XPEV, DLO) accounted for 94.5% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ALHC | Alignment Healthcare Inc | Stock-Other | 20.50% | — | — | |
| 2 | XPEV | XPeng Inc. | Stock-Other | 15.11% | -6.73% | — | |
| 3 | DLO | DLocal Limited | Stock-Other | 14.53% | -7.31% | — | |
| 4 | 8DT | Squarespace Inc - Class A | Stock-Other | 14.01% | — | — | |
| 5 | ALKT | Alkami Technology Inc | Stock-Other | 13.92% | +0.89% | -9.70% | |
| 6 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.40% | -2.50% | EXIT | |
| 7 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.27% | — | — | |
| 8 | PHVS | Pharvaris N.V. | Stock-Other | 3.97% | -2.77% | — | |
| 9 | EWCZ | European Wax Center Inc-a | Stock-Other | 2.53% | -3.53% | EXIT | |
| 10 | BLND | Blend Labs Inc-a | Stock-Other | 2.04% | — | — | |
| 11 | RPRX | Royalty Pharma plc | Stock-Healthcare | 1.21% | — | — | |
| 12 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.14% | — | — | |
| 13 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.12% | — | — | |
| 14 | RSKD | Riskified Ltd. | Stock-Other | 0.72% | -0.05% | — | |
| 15 | ✓ | Acelyrin Inc | Stock-Other | 0.41% | — | — | |
| 16 | 5ZZ0 | Contextlogic Inc - A | Stock-Other | 0.09% | — | — | |
| 17 | GROV | Grove Collaborative Holdings | Stock-Other | 0.04% | -0.04% | — | |
| 18 | ADAG | Adagene Inc-adr | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALHC | Alignment Healthcare Inc | +5.5% | — | Unchanged |
| 2 | 260 | Centessa Pharmaceuticals-adr | +1.7% | — | Unchanged |
| 3 | BLND | Blend Labs Inc-a | +0.6% | — | Unchanged |
| 4 | AKRO | Akero Therapeutics Inc | +0.4% | — | Unchanged |
| 5 | ✓ | Acelyrin Inc | — | — | Unchanged |
| 6 | GROV | Grove Collaborative Holdings | 0% | — | Unchanged |
| 7 | ADAG | Adagene Inc-adr | 0% | — | Unchanged |
| 8 | 5ZZ0 | Contextlogic Inc - A | 0% | — | Unchanged |
| 9 | RPRX | Royalty Pharma plc | 0% | — | Unchanged |
| 10 | ✓ | Third Harmonic Bio Inc | -0.1% | — | Unchanged |
| 11 | IMCR | Immunocore Holdings Plc-adr | -0.2% | — | Unchanged |
| 12 | RSKD | Riskified Ltd. | -0.4% | — | Unchanged |
| 13 | OPEN | Opendoor Technologies Inc | -0.4% | EXIT | Sold out |
| 14 | PHVS | Pharvaris N.V. | -0.5% | — | Unchanged |
| 15 | 8DT | Squarespace Inc - Class A | -0.6% | — | Unchanged |
| 16 | XPEV | XPeng Inc. | -1.3% | — | Unchanged |
| 17 | ALKT | Alkami Technology Inc | -1.5% | -9.70% | Trim |
| 18 | EWCZ | European Wax Center Inc-a | -1.6% | — | Unchanged |
| 19 | DLO | DLocal Limited | -1.7% | — | Unchanged |
According to official SEC Form 13F filings, General Atlantic, L.p. reported a total U.S. public equity portfolio value of $2.9B across 18 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top Position Liquidated / Trimmed
OPEN
前期市值: $11.6M
During Q3 2024, General Atlantic, L.p.'s top holdings by market value included ALHC (20.5%)、XPEV (15.1%)、DLO (14.5%). The largest single position, ALHC, represented 20.5% of total portfolio value.
In Q3 2024, General Atlantic, L.p. made 2 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.